Market revenue in 2023 | USD 866.9 million |
Market revenue in 2030 | USD 1,372.2 million |
Growth rate | 6.8% (CAGR from 2023 to 2030) |
Largest segment | Regulatory writing & publishing |
Fastest growing segment | Other Services |
Historical data covered | 2018 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Regulatory Consulting, Legal Representation, Regulatory Writing & Publishing, Product Registration & Clinical Trial Applications, Other Services |
Key market players worldwide | Genpact Ltd, Icon PLC, Promedica International, Wuxi AppTec Co Ltd, Medpace Holdings Inc, Charles River Laboratories International Inc, Labcorp Drug Development, Cencora Inc, Pharmexon, QVigilance, Voisin Consulting Life Sciences, Accell, Criterium Inc., Freyr Solutions, PharmaLex, NDA Regulatory Service GmbH, BlueReg Group, Cambridge Regulatory Services |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to biopharmaceutical regulatory affairs market will help companies and investors design strategic landscapes.
Regulatory writing & publishing was the largest segment with a revenue share of 31.53% in 2023. Horizon Databook has segmented the Europe biopharmaceutical regulatory affairs market based on regulatory consulting, legal representation, regulatory writing & publishing, product registration & clinical trial applications, other services covering the revenue growth of each sub-segment from 2018 to 2030.
Europe is considered to be a decentralized pharmaceutical market. Entry into the market requires players to know extensively about different regulatory procedures in various European Union (EU) member states.
Small- and mid-size biopharmaceutical companies with a lack of regulatory affairs department hire a regulatory consultant or a legal representative to assist them through various stages of regulatory approval processes required for commercializing their product in Europe.
The European Medicine Agency (EMA), Europe’s regulatory agency, covers around 25.0% of global pharmaceutical sales. This is one of the leading drivers of outsourcing regulatory affairs in the life sciences sector, as a higher number of drugs for regulatory approval would increase the demand for regulatory services by life sciences companies in Europe.
Horizon Databook provides a detailed overview of continent-level data and insights on the Europe biopharmaceutical regulatory affairs market , including forecasts for subscribers. This continent databook contains high-level insights into Europe biopharmaceutical regulatory affairs market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account